The Enantiomer of ADB-FUBINACA is defined in a 2009 Pfizer patent and has been stated to be a strong agonist of the CB1 receptor and the CB2 receptor with EC50 values of 1.2 nM and 3. five nM, respectively. ADB-FUBINACA capabilities a carboxamide organization on the 3-indazole position, like SDB-001 and STS-135. ADB-FUBINACA seems to be made from rational drug design because it differs from AB-FUBINACA handiest via way of means of substituting the isopropyl organization with a tert-butyl organization. An analog of ADB-FUBINACA, ADSB-FUB-187, containing an extra functionalized carboxamide substituent changed into lately stated.
Gem88
Keluaranmejavip
Steroidskaufen
B52 Club1
Soc88
855jl
Nowgoal
Mole4d
Central Rail Supply Ltd.
Go88